IP Library Granted Patent US 7,387,603
Granted Patent B2
US 7,387,603 · App. 10/999,824 · Granted Jun 17, 2008

Incontinence treatment device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,387,603
App. No.
10/999,824
Granted
Jun 17, 2008
Kind
B2
Abstract

A device and method for treatment of urinary stress incontinence. At least one electrode is implanted in a pelvic muscle of a patient. A control unit receives signals indicative of abdominal stress in the patient and responsive thereto applies an electrical waveform to the electrode which stimulates the muscle to contract, so as to inhibit involuntary urine flow through the patient's urethra due to the stress.

Claims (44)

1. An apparatus comprising:

at least one elongated electrode structure comprising at least one electrode, the elongated electrode structure being adapted to sense an electromyographic signal indicative of urinary incontinence from a pelvic muscle of a patient; and

a control unit coupled to the at least one electrode and comprising an electrical waveform output that is adapted to be applied to the pelvic muscle through the at least one electrode, the control unit comprising a processor that analyzes the electromyographic signal and that controls the electrical waveform output as a function of the electromyographic signal to control the urinary incontinence; and

wherein the at least one electrode comprises a flexible intra-muscular electrode.

2. The apparatus according to claim 1 , wherein the at least one elongated electrode structure is adapted to be implanted in the pelvic muscle.

3. The apparatus according to claim 1 , wherein the at least one elongated electrode structure is adapted to be implanted in contact with a levator ani muscle portion of the pelvic muscle.

4. The apparatus according to claim 1 , wherein the at least one elongated electrode structure is adapted to be implanted in contact with an urethral sphincter muscle portion of the pelvic muscle.

5. The apparatus according to claim 1 , wherein the at least one elongated electrode structure is adapted to be implanted in contact with a portion of the pelvic muscle that is adjacent to an urethral sphincter muscle.

6. The apparatus according to claim 1 , wherein the at least one elongated electrode structure is adapted to be implanted in a levator ani muscle portion of the pelvic muscle.

7. The apparatus according to claim 1 , wherein the at least one elongated electrode structure is adapted to be implanted in an urethral sphincter muscle portion of the pelvic muscle.

8. The apparatus according to claim 1 , wherein the at least one elongated electrode structure is adapted to be implanted in the a portion of the pelvic muscle that is adjacent to a urethral sphincter muscle.

9. The apparatus according to claim 1 , wherein the electrical waveform output comprises a plurality of electrical pulses having pulse width durations in a range of 0.1 ms to 2 ms.

10. The apparatus according to claim 1 , wherein the at least one electrode comprises a single unipolar electrode.

11. The apparatus according to claim 1 , wherein the at least one electrode comprises a pair of bipolar electrodes.

12. The apparatus according to claim 1 , wherein the electrical waveform output comprises a biphasic electrical waveform.

13. The apparatus according to claim 1 , wherein the control unit controls the electrical waveform output to treat urinary incontinence of the patient.

14. The apparatus according to claim 1 , wherein the control unit controls the electrical waveform output to treat urinary urge incontinence.

15. The apparatus according to claim 1 , wherein the control unit controls the electrical waveform output to treat urinary stress incontinence.

16. The apparatus according to claim 1 , wherein the control unit comprises a pulse generator that actuates the electrical waveform output to terminate after a predetermined period of time.

17. The apparatus according to claim 16 , wherein the pulse generator actuates the pulse generator to terminate after 5 seconds.

18. The apparatus according to claim 16 , wherein the control unit controls the pulse generator to reapply the electrical waveform output to the muscle through the at least one electrode after termination of the application of the electrical waveform output.

19. The apparatus according to claim 1 wherein the control unit comprises a switch that is connected to the electrode and controlled by the control unit, and the switch disconnects the analyzing of the electromyographic signal when the electrical waveform output is provided.

20. The apparatus according to claim 1 wherein the control unit comprises an impedance sensor coupled to the electrode, and the impedance sensor measures tissue impedance.

21. The apparatus according to claim 1 wherein the control unit comprises a differential preamplifier with a preamplifier input that is coupled to the electrode and a preamplifier output; and wherein the control unit further comprises an amplifier with an amplifier input that receives the preamplifier output.

22. The apparatus according to claim 1 wherein the control unit comprises a lower power A/D converter that analyzes continuously at a lower sampling rate, and a higher power A/D converter that analyzes at a higher rate when the electromyographic signal is sensed.

23. The apparatus according to claim 22 wherein the control unit comprises a first-in first-out queue that receives an A/D output of the lower power A/D converter.

24. An apparatus comprising:

at least one elongated electrode structure comprising at least one electrode, the elongated electrode structure being adapted to sense an electromyographic signal indicative of urinary incontinence from a pelvic muscle of a patient; and

a control unit coupled to the at least one electrode and comprising an electrical waveform output that is adapted to be applied to the muscle through the at least one electrode, the control unit comprising a processor that analyzes the electromyographic signal and that controls the electrical waveform output as a function of the electromyographic signal to control the urinary incontinence; and

wherein the control unit controls the pulse width duration of the waveform to a range of pulse width durations that includes 2 ms.

25. The apparatus according to claim 24 wherein the control unit comprises a switch that is connected to the electrode and controlled by the control unit, and the switch disconnects the analyzing of the electromyographic signal when the electrical waveform output is provided.

26. The apparatus according to claim 24 wherein the control unit comprises an impedance sensor coupled to the electrode, and the impedance sensor measures tissue impedance.

27. The apparatus according to claim 24 wherein the control unit comprises a differential preamplifier with a preamplifier input that is coupled to the electrode and a preamplifier output; and wherein the control unit further comprises an amplifier with an amplifier input that receives the preamplifier output.

28. The apparatus according to claim 24 wherein the control unit comprises a lower power A/D converter that analyzes continuously at a lower sampling rate, and a higher power A/D converter that analyzes at a higher rate when the electromyographic signal is sensed.

29. The apparatus according to claim 28 wherein the control unit comprises a first-in first-out queue that receives an A/D output of the lower power A/D converter.

30. An apparatus comprising:

at least one elongated electrode structure comprising at least one electrode, the elongated electrode structure being adapted to sense an electromyographic signal indicative of urinary incontinence from a pelvic muscle of a patient; and

a control unit implanted in the patient and coupled to the at least one electrode structure and comprising an electrical waveform output comprising a plurality of electrical pulses that is applied to the pelvic muscle though the electrode structure the control unit comprising a processor that analyzes the electromyographic signal and that controls the electrical waveform output as a function of the electromyographic signal to control the urinary incontinence;

wherein the control unit includes a variable adaptive threshold level that increases as a function of an average of the electromyographic signal.

31. The apparatus according to claim 30 wherein the control unit comprises a switch that is connected to the electrode and controlled by the control unit, and the switch disconnects the analyzing of the electromyographic signal when the electrical waveform output is provided.

32. The apparatus according to claim 30 wherein the control unit comprises an impedance sensor coupled to the electrode, and the impedance sensor measures tissue impedance.

33. The apparatus according to claim 30 wherein the control unit comprises a differential preamplifier with a preamplifier input that is coupled to the electrode and a preamplifier output; and wherein the control unit further comprises an amplifier with an amplifier input that receives the preamplifier output.

34. The apparatus according to claim 30 wherein the control unit comprises a lower power A/D converter that analyzes continuously at a lower sampling rate, and a higher power A/D converter that analyzes at a higher rate when the electromyographic signal is sensed.

35. The apparatus according to claim 34 wherein the control unit comprises a first-in first-out queue that receives an A/D output of the lower power A/D converter.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0278 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0607. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 11, 2016
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 037514/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: AMS RESEARCH, LLC
To: APHRODITE WOMEN'S HEALTH, LLC
Reel/Frame 037473/0425 →
CHANGE OF NAME Recorded Jan 11, 2016
From: APHRODITE WOMEN'S HEALTH, LLC
To: ASTORA WOMEN'S HEALTH, LLC
Reel/Frame 037473/0535 →
CHANGE OF NAME Recorded Dec 15, 2015
From: AMS RESEARCH CORPATION
To: AMS RESEARCH, LLC
Reel/Frame 037300/0607 →
RELEASE OF SECURITY INTEREST Recorded Aug 6, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: AMERICAN MEDICAL SYSTEMS, LLC; AMS RESEARCH, LLC; LASERSCOPE
Reel/Frame 036285/0146 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: AMS RESEARCH CORPORATION
Reel/Frame 032380/0053 →
SECURITY AGREEMENT Recorded Jul 22, 2011
From: AMS RESEARCH CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026632/0535 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Apr 27, 2011
From: MEDTRONIC, INC.
To: BIO CONTROL MEDICAL (B.C.M.) LTD
Reel/Frame 026186/0580 →
SECURITY AGREEMENT Recorded May 20, 2010
From: BIO CONTROL MEDICAL (B.C.M.) LTD
To: MEDTRONIC, INC.
Reel/Frame 024411/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2008
From: GROSS, YOSSI; COHEN, EHUD; NISSENKORN, ISRAEL; LIFSCHITZ, DAVID
To: BIOCONTROL MEDICAL LTD.
Reel/Frame 021073/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2007
From: BIOCONTROL MEDICAL LTD.
To: AMS RESEARCH CORPORATION
Reel/Frame 019900/0704 →